Cubist Pharmaceuticals Inc. agreed to license its antibiotic Cubicin to Teva Pharmaceutical Industries Ltd., resolving a patent dispute.
Teva can start selling its generic version in June 2018 if Cubist is granted a six-month extension of marketing protection for pediatric use, Lexington, Massachusetts-based Cubist said yesterday in a statement. The patent is due to expire in September 2019. Without pediatric clearance, Teva may sell Cubicin starting in December 2017.
